Clinical Trial Update: A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body [Phase 1, Phase 2]

View source ↗

Summary

First-in-human Phase 1/2 trial evaluating REGN10597 alone or with cemiplimab in adults with melanoma, clear-cell renal cell carcinoma, and other advanced solid …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Melanoma
• Solid Tumors

Drugs mentioned

• Cemiplimab (cemiplimab)
• REGN10597

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC) | Phase 1, Phase 2 | Status: RECRUITING